Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46312

1.

Latex hypersensitivity to injection devices for biologic therapies in psoriasis patients.

Johnson C, Zumwalt M, Anderson N.

Cutis. 2018 Aug;102(2):116-118.

PMID:
30235360
2.

Inflammatory linear verrucous epidermal nevus responsive to 308-nm excimer laser treatment.

Grgurich E, Gupta N, Owen R, Purcell SM.

Cutis. 2018 Aug;102(2):111-114.

PMID:
30235359
3.

Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients.

Khan SA, Agrawal S, Baral N, Lamsal M.

Psoriasis (Auckl). 2018 Sep 4;8:59-63. doi: 10.2147/PTT.S174119. eCollection 2018.

4.

Disease Burden and Treatment Patterns of Psoriasis in Russia: A Real-World Patient and Dermatologist Survey.

Kubanov AA, Bakulev AL, Fitileva TV, Novoderezhkina E, Gilloteau I, Tian H, Howe T, Pietri G.

Dermatol Ther (Heidelb). 2018 Sep 19. doi: 10.1007/s13555-018-0262-1. [Epub ahead of print]

PMID:
30232682
5.
6.

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP.

Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, Ozawa A, Kanekura T, Kurosawa M, Komine M, Nakajima K, Sano S, Nemoto O, Muto M, Imai Y, Yamanishi K, Aoyama Y, Iwatsuki K; Japanese Dermatological Association Guidelines Development Committee for the Guidelines for the Management and Treatment of Generalized Pustular Psoriasis.

J Dermatol. 2018 Sep 19. doi: 10.1111/1346-8138.14523. [Epub ahead of print]

PMID:
30230572
7.

Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain.

Hu B, Hu H, Yin M, Sun Z, Chen X, Li Y, Sun Z, Liu C, Li L, Qiu Y.

Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31877. [Epub ahead of print]

PMID:
30230528
8.

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.

McInnes IB, Nash P, Ritchlin C, Choy EH, Kanters S, Thom H, Gandhi K, Pricop L, Jugl SM.

J Comp Eff Res. 2018 Sep 19. doi: 10.2217/cer-2018-0075. [Epub ahead of print]

PMID:
30230361
9.

When side effect becomes the effect: Efficacy of capecitabine in refractory psoriasis.

Karakas Y, Vural S, Diker O, Dizdar O.

Dermatol Ther. 2018 Sep 19:e12629. doi: 10.1111/dth.12629. [Epub ahead of print] No abstract available.

PMID:
30230162
10.

HIF-1α-mediated BMP6 down-regulation leads to hyperproliferation and abnormal differentiation of keratinocytes in vitro.

Kim JH, Bae HC, Kim J, Lee H, Ryu WI, Son ED, Lee TR, Jeong SH, Son SW.

Exp Dermatol. 2018 Sep 19. doi: 10.1111/exd.13785. [Epub ahead of print]

PMID:
30230035
11.

Psoriasin (S100A7) and koebserisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis.

Gonzalez-Cantero A, Gonzalez-Cantero J, Sanchez-Moya AI, Schoendorff-Ortega C, Barderas MG, Perez-Hortet C.

Clin Exp Dermatol. 2018 Sep 19. doi: 10.1111/ced.13764. [Epub ahead of print] No abstract available.

PMID:
30229984
12.

Risk of first-time and recurrent depression in patients with psoriasis - a population-based cohort study.

Egeberg A, Thyssen JP, Wu JJ, Skov L.

Br J Dermatol. 2018 Sep 19. doi: 10.1111/bjd.17208. [Epub ahead of print]

PMID:
30229872
13.

Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.

Radi G, Campanati A, Diotallevi F, Molinelli E, Offidani A.

G Ital Dermatol Venereol. 2018 Sep 18. doi: 10.23736/S0392-0488.18.06095-9. [Epub ahead of print]

PMID:
30229640
14.

Long-term safety results from a Phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion in moderate-to-severe plaque psoriasis.

Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R.

J Am Acad Dermatol. 2018 Sep 15. pii: S0190-9622(18)32569-6. doi: 10.1016/j.jaad.2018.09.002. [Epub ahead of print] No abstract available.

PMID:
30227193
15.

Rouleaux: a microscopic clue that helps distinguish psoriasis from dermatitis.

Luo Y, Keeling B, Forcucci JA, Elston DM.

J Am Acad Dermatol. 2018 Sep 15. pii: S0190-9622(18)32572-6. doi: 10.1016/j.jaad.2018.09.005. [Epub ahead of print] No abstract available.

PMID:
30227191
16.

Linking of psoriasis with osteopenia and osteoporosis: A cross-sectional study.

Martinez-Lopez A, Blasco-Morente G, Giron-Prieto MS, Arrabal-Polo MA, Luque-Valenzuela M, Luna-Del Castillo JD, Tercedor-Sanchez J, Arias-Santiago S.

Indian J Dermatol Venereol Leprol. 2018 Sep 17. doi: 10.4103/ijdvl.IJDVL_831_17. [Epub ahead of print]

PMID:
30226478
17.

Assessment of nail unit structures by ultrasound in patients with psoriatic arthritis and their correlations with disease activity indices: a case-control study.

Mondal S, Dutta S, Lahiri D, Sinha D, Sircar G, Mandal AK, Kejriwal M, Ghosh A.

Rheumatol Int. 2018 Sep 17. doi: 10.1007/s00296-018-4160-8. [Epub ahead of print]

PMID:
30225658
18.

Skin Disease Recognition Method Based on Image Color and Texture Features.

Wei LS, Gan Q, Ji T.

Comput Math Methods Med. 2018 Aug 26;2018:8145713. doi: 10.1155/2018/8145713. eCollection 2018.

19.

IκBζ is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes.

Müller A, Hennig A, Lorscheid S, Grondona P, Schulze-Osthoff K, Hailfinger S, Kramer D.

Proc Natl Acad Sci U S A. 2018 Sep 17. pii: 201801377. doi: 10.1073/pnas.1801377115. [Epub ahead of print]

20.

Bayesian Design of Proof-of-Concept Trials.

Fisch R, Jones I, Jones J, Kerman J, Rosenkranz GK, Schmidli H.

Ther Innov Regul Sci. 2015 Jan;49(1):155-162. doi: 10.1177/2168479014533970.

PMID:
30222466

Supplemental Content

Loading ...
Support Center